Crinetics Pharmaceuticals, Inc.

Hello, everyone. Thank you for joining us and welcome to the Krenetics Pharmaceuticals first quarter 2026 financial results. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question, please press star one to raise your hand. To withdraw your question, press star one again. I will now hand the conference over to Gayatri Dwarkar, Head of Investor Relations. Gayatri, please go ahead.

Thank you, operator. Good afternoon, everyone. And thank you for joining us. Thank you, operator. Good afternoon, everyone. And thank you for joining us to discuss the first quarter 2026 results. Today on the call, we have Dr. Scott Struthers, founder and chief executive officer, Isabel Califonos, chief commercial officer, Dr. Alan Krasner, chief endocrinologist, and Toby Schilke, chief financial officer. Please note there's a slide deck for today's presentation, which is in the events and presentation section of the investors page on the Krenetics website. In addition, a press release was issued earlier today and is also available on the corporate website. Slide two. As a reminder, we'll be making forward-looking statements, and I invite you to learn more about the risks and uncertainties associated with these statements as disclosed in our SEC filings. Such forward-looking statements are not a guarantee of performance, and the company's actual results could differ materially from those stated or implied in such statements due to risks and certainties associated with the company's business. In particular, today we will be reviewing launch progress to date, our commercialization plans, future performance, and other data about the acromegaly market, which are all necessarily subject to a high degree of uncertainty and risk. These forward-looking statements are qualified in their entirety by the cautionary statements contained in today's news release, the company's other news releases, and Kinetics SEC filings, including its annual report on Form 10-K and quarterly reports on Form 10-Q. In addition, this call will include certain non-GAAP financial measures. A presentation of the most directly comparable GAAP financial measures and reconciliations thereto are included in today's news release accessible from the investor relations section of our website. I would also like to specify that the content of this conference call contains time-sensitive information that's accurate only as of this live broadcast. Chronetics takes no obligation to review or update any forward-looking statements to reflect events or circumstances after the date of this conference call. With that, I'll hand the call over to Scott.

Thanks, Gayathri. Thank you for joining us on today's call. Moving on to slide four. This has been another strong quarter of executing our plan to make Chronetics the premier endocrine company. Chronetics is committed to translating the complexities of cutting-edge endocrinology into real value for patients. And with the launch of Palsonify, we are delivering on that commitment every day. We've made great strides in building the business by consistently adding patients every week to the pool that will be helped by Palsonify for many years to come. The consistent positive feedback we continue to receive from both patients and HCPs is especially gratifying. We have also meaningfully advanced our deep clinical stage pipeline with four major trials running and recruiting nicely. These represent blockbuster opportunities across several areas. And we continue to grow the pipeline with multiple compounds and IND-enabling activities with more to come from our ongoing discovery efforts. We have built a company that has proven it can discover, develop, and deliver its own novel therapeutics, and we are well-capitalized to continue to execute this growth strategy and drive value creation. I'm very proud of our team's strong execution across all dimensions of the company's first launch. This collective effort has translated into 232 additional patient enrollments and 10.3 million in net product revenue for the quarter. And we are making strong progress with access, including continually driving higher conversion from enrollment forms to patients starting PalSanify and growing reimbursement as coverage on formularies expands. We expect low discontinuation rates based on our clinical studies. Therefore, the number of patients on Palsonify should continue to compound. We continue to see momentum build on all fronts in the second quarter. While it's early days, we are confident in our growth trajectory. Palsonify sets a new standard of care for the treatment of acromegaly and is on track to become the most prescribed brand. Over the last few weeks, we've continued to advance PalSanify globally, including the European Commission approval of our MAA, the JNDA submission in Japan by our partners at SKK, and our MAA submission in Brazil. These milestones underscore the strength of PalSanify's clinical data and the significant unmet need amongst patients around the world. As we expand internationally, we are taking a disciplined market by market approach prioritizing geographies with clear regulatory and reimbursement pathways, and pacing investment in line with an increasingly dynamic global pricing and access environment. All in all, it's clear that Palsanify is positioned to become the leading acromegaly treatment, and Chronetics has an exceptionally equipped team to bring it to the patients in need. With our early commercial success, continued clinical execution, and a robust balance sheet to support the advancement of our innovative pipeline, Krenetics is well positioned to generate value for all stakeholders in both the near and long term. I'll now turn the call over to Isabel to discuss the Palsonify launch in more detail. Isabel?